Login
Companies $MLTX
$11.73 +$0.00 (0.0%) After hours
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics

moonlaketx.com

What Do They Do?

Develops sonelokimab, an experimental treatment for inflammatory skin and joint diseases, for patients with conditions such as hidradenitis suppurativa and psoriatic arthritis.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −14% (Loss)
vs −$69.7M in Q3 FY2025

Broader clinical focus The earlier report described hidradenitis suppurativa and psoriatic arthritis as initial development targets; the latest report identifies axial spondyloarthritis and palmoplantar pustulosis as additional target diseases.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support